9 results about "Rifamycin" patented technology

The present invention relates to novel rufamycin analogs that target the ClpC1 protease. The compounds of the present invention have antibacterial activity, e.g., with anti-tuberculosis properties, and are useful in the treatment of e.g. Tuberculosis.

The present invention provides use of a rifamycin-nitroimidazole conjugate molecule, or deuterated derivatives thereof, metabolites thereof, pharmaceutically acceptable salts thereof, or prodrugs thereof in the preparation of a drug for the treatment or prevention of a disease caused by Mycobacterium tuberculosis infection. The rifamycin-nitroimidazole conjugate molecule has a structure represented by formula I.The rifamycin-nitroimidazole conjugate molecule or the deuterated derivatives thereof, the metabolites thereof, the pharmaceutically acceptable salts thereof, or the prodrugs thereof in the present invention inhibit Mycobacterium tuberculosis comprising multi-drug-resistant (MDR) and extensive drug-resistant Mycobacterium tuberculosis (XDR-TB), and then are used for treating or preventing infections and a disease caused by Mycobacterium tuberculosis.

The utility model discloses a rifamycin SV strain breeding device which comprises a supporting table, a base, a cultivation structure and a ventilation structure, the base is arranged on the supporting table, the cultivation structure is arranged on the base, and the ventilation structure is arranged on the cultivation structure. The cultivation structure comprises a base plate, a first fence, a second fence, a vent hole pipe, a supporting column, a connector, a protective cover and a flow guide strip, the base plate is fixedly arranged above the base, the first fence is vertically arranged on the outer edge of the upper portion of the base plate, and the second fence is vertically arranged in the middle of the upper portion of the base plate. The utility model belongs to the technical field of strain breeding equipment, particularly relates to a rifamycin SV strain breeding device, and effectively solves the problems that a plurality of breeding trays of the rifamycin SV strain breeding device are arranged, so that cross infection is easily caused in the culture process, breeding failure or similar quality of bred strains is caused, and the breeding efficiency is high. And excellent strains cannot be bred.

The utility model discloses a centrifugal separation device for rifamycin production, which comprises a box body, a separation assembly and a drainage assembly, the upper end of the box body is provided with a sealing cover through a lock catch, the separation assembly is arranged in an inner cavity of the box body, and the bottom end of the box body is communicated with the drainage assembly; the drainage assembly comprises a drainage box, the top end of the drainage box is communicated with the bottom end of the box body, a drainage opening is formed in the bottom end of the drainage box, a collection box is placed below the drainage opening, and an annular sensor is installed on the inner wall of the lower section of the box body. The problems that when a separation device in the prior art is used, after being thrown out, liquid in a separation cylinder needs to flow into a drainage cavity at the bottom end in a boss cavity and then flow out of a drainage pipe, but a flow switch sensor is arranged on the drainage pipe, so that the distance between the flow switch sensor and the water inlet end of the drainage cavity is long, and the separation effect is poor are solved. Therefore, the detection effect of the sensor is easily influenced.

Disclosed herein are compounds of Formula I and methods for using the same for treating or preventing an infection caused by a Mycobacterium in a subject in need thereof. The method comprises administering to the subject the compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound of Formula I.

The application discloses a preparation method of high-efficiency ethambutol-pyrazine-rifampicin-isoniazid tablets, which comprises the following steps: (1) preparing isoniazid granules by mixing isoniazid, pyrazine amide, microcrystalline cellulose and pregelatinized starch; and preparing ethambutol hydrochloride granules by mixing ethambutol hydrochloride, microcrystalline cellulose and pregelatinized starch; (2) adding an aqueous solution of povidone K30 into the isoniazid granules to obtain isoniazid soft material, and adding a mixed aqueous solution of povidone K30 and sodium dodecyl sulfate into the ethambutol hydrochloride granules to prepare ethambutol hydrochloride soft material; granulating, drying and whole-granulating to obtain ethambutol hydrochloride dry granules; (3) mixing the ethambutol hydrochloride dry granules, talc and rifampicin, stirring, then adding corn starch, isoniazid dry granules, crosslinked povidone and magnesium stearate, uniformly mixing, tabletting, coating and obtaining finished products. The preparation method is optimized, the disintegration time of the tablets is shortened, the dissolution of the active ingredients of the medicine is accelerated, and the drug efficacy is improved. In addition, the solubility of rifampicin is significantly improved by preparing a rifampicin inclusion compound, and the drug efficacy is improved.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and / or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections.

The invention relates to the field of new biological materials, in particular to an antibacterial slow-release biological patch obtained by packaging at least two antibiotics with an acellular matrix material. The antibacterial slow-release biological patch is obtained by packaging at least two antibiotics with an acellular matrix material, and the antibiotics at least comprise rifamycin antibiotics; the antibacterial slow-release biological patch at least comprises a region R and a region L, the overlapping rate of the edge of the region R and the edge of the patch is smaller than 100%, and the drug concentration of rifamycin antibiotics in the region R is 300-1300 micrograms / cm < 2 >. The coating-free drug-loaded sustained-release system based on a lamination process kills bacteria in a short period, prevents colonization and reproduction of bacteria in a wound / patch, realizes synergistic and continuous release of antibiotics along with a wound healing process, guides tissue regeneration and synchronously realizes degradation, is applied to a high-incidence infection period of a surgical operation, reduces adhesion, and has a good application prospect. The abdominal wall strength is enhanced, and the growth of wound granulation tissues is promoted.